Portage, MI, United States of America

Heinrich Josef Schostarez

This inventor holds 20 USPTO granted patents and 3 published patent applications, primarily in Pharmaceutical Chemistry. Top assignees: Pharmacia & Upjohn Company, The Upjohn Co., Pharmacia & Upjohn. Active years: 1988-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heinrich Josef Schostarez. Retrieved from https://idiyas.com/inventor/heinrich-josef-schostarez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 

% Patents Active = 65.0

Average Co-Inventor Count = 2.7

ph-index = 8

Forward Citations = 153(Granted Patents)


Company Filing History:


Years Active: 1988-2008

Loading Chart...
Areas of Expertise:
Alzheimer's Disease
Protein Tyrosine Phosphatase
Aminoguanidine Carboxylates
Statine Derivatives
Thiadiazole Derivatives
Renin Inhibitors
Hair Growth Stimulation
Diabetes Mellitus
Aza Hydroxylated Compounds
Diaminediols
Aminediols
5-Fluoro-Pyrimidinetriamine
20 patents (USPTO):Explore Patents

Title: Innovations of Heinrich Josef Schostarez in Alzheimer’s Disease Treatment

Introduction: Heinrich Josef Schostarez is an accomplished inventor based in Portage, MI, known for his significant contributions in the field of pharmaceuticals, particularly focusing on compounds that aim to treat Alzheimer’s disease. With a prolific portfolio of 20 patents, Schostarez has demonstrated a commitment to advancing medical science and improving patient outcomes.

Latest Patents: Among his most recent inventions are two key patents that show promise in the treatment of Alzheimer’s disease. The first patent involves amine 1,2- and 1,3-diol compounds, which are disclosed as useful in combating Alzheimer's disease and similar conditions. These compounds inhibit the beta-secretase enzyme, which is crucial in reducing A beta peptide formation in mammals, thereby playing a role in the progression of Alzheimer's disease. His second patent details statine derivatives that also target the beta-secretase enzyme for the treatment of Alzheimer's, emphasizing the importance of these compounds in pharmaceutical compositions designed to mitigate the effects of the disease.

Career Highlights: Schostarez has made significant strides in pharmaceutical research through his work at reputable companies such as Pharmacia & Upjohn Company and The Upjohn Company. These positions allowed him to engage deeply with innovative research and development processes, fostering his ability to create impactful inventions in the industry.

Collaborations: Throughout his career, Heinrich has collaborated with notable professionals in the field, including Robert Alan Chrusciel and Scott D Larsen. These partnerships have contributed to advancing research initiatives and have likely provided a robust collaborative framework for developing new treatment options.

Conclusion: Heinrich Josef Schostarez exemplifies the spirit of innovation in the pharmaceutical industry with his focus on Alzheimer's disease treatment. His dedication to researching and developing compounds that inhibit critical enzymes offers hope for effective therapies and contributes to the broader fight against neurodegenerative diseases. With a strong foundation of patents and a noteworthy career, Schostarez continues to influence the landscape of pharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…